Illumina Appoints Ex-Labcorp CEO David P. King, Who Tripled Labcorp’s Size
Illumina elected former Labcorp CEO David P. King to its Board of Directors following its annual shareholders meeting, replacing three retiring directors. Under King's leadership at Labcorp from 2007 to 2019, the company tripled in size through organic growth and acquisitions, bolstering Illumina's clinical strategy.
1. Board Election
Illumina confirmed at its 2026 annual shareholders meeting that David P. King, former Labcorp Chairman and CEO, has been elected to its Board of Directors. He fills vacancies created by the retirement of Frances Arnold, Robert S. Epstein and Gary S. Guthart.
2. Leadership Background
King served as Labcorp’s CEO and Executive Chairman from 2007 to 2019, overseeing its entry into the Fortune 500 and tripling its size through a combination of organic growth and strategic acquisitions. He currently advises healthcare companies through KingMan LLC and holds board roles at Privia Health Group and Smith & Nephew, among others.
3. Strategic Implications
King’s regulatory knowledge and diagnostics expertise are expected to accelerate Illumina’s strategy to integrate genomic technologies into standard clinical care. His board governance experience will support the company’s long-term goal of expanding its clinical sequencing footprint and driving patient-centric innovation.